Format

Send to

Choose Destination
Clin Pharmacol Ther. 2016 Nov;100(5):423-426. doi: 10.1002/cpt.405. Epub 2016 Jul 21.

Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.

Author information

1
University of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA.
2
University of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA. kathy.giacomini@ucsf.edu.
3
University of California San Francisco, Department of Bioengineering and Therapeutic Sciences, San Francisco, California, USA. michiaki.kubo@riken.jp.

Abstract

Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.

PMID:
27256705
PMCID:
PMC5056156
DOI:
10.1002/cpt.405
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center